NCT06441591View on ClinicalTrials.gov

Clinical Outcome of Vinpocetine in Diabetic Nephropathy

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2025

Conditions
Diabetic Kidney DiseaseDiabetic Nephropathies
Interventions
DRUG

Vinpocetine

Vinca derivative of apovincamine, phosphodiestrase 1 inhibitor, sodium-gated voltage channel

DRUG

Standard Therapy

Anti-hypertensive and anti-diabetic medications according to the the institution's protocol

OTHER

Placebo

Starch-filled capsules, matching those of the intervention

Trial Locations (2)

11588

NOT_YET_RECRUITING

Ain Shams University Hospital, Cairo

RECRUITING

Ain Shams Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER